High Tide Inc.
HITI is a low-conviction BUY because the market is still valuing it like a struggling Canadian cannabis retailer at 0.46x sales, while the business is shifting toward a higher-margin German distribution profit engine that just produced its best quarter.
The market is still pricing HITI as if it were mainly a low-margin, structurally challenged Canadian cannabis retailer. That view is now incomplete. The latest quarter showed a different company shape: CAD 179.3M of revenue, up 30% y/y, an eight-quarter high 27% gross margin, and CAD 13.9M of adjusted EBITDA. More important than the quarter itself, the source of profit changed. Germany, through Remexian, is now the clearest marginal earnings driver, with market share up from 6.5% to 14.1% and management saying Q2 is more representative than Q1 for the go-forward picture.
That matters because HITI at $2.56 and 0.46x sales does not need perfection. It needs proof that positive earnings can become repeatable rather than episodic. If Remexian can hold around 25% gross margin, and if Canadian retail simply avoids further deterioration while the company adds stores within the 20-30 target, the earnings base should look materially better over the next year than trailing FY2025 suggests. Trailing EPS of -$0.45 is the wrong anchor for a business that just posted positive net income and free cash flow in the quarter, even if annual FCF still rounds to $0.0B in the supplied snapshot.
The case depends on three things. First, Germany must remain a real structural profit pool, not a one-quarter spike tied to shipment timing. Second, Canadian retail cannot keep sliding meaningfully from here, because same-store sales -1.2% already shows the domestic business is not carrying the thesis. Third, management must prove the ugly earnings volatility, including the January 2026 EPS miss, was noise from timing and mix rather than evidence of a fragile model.
Low conviction is appropriate because this is not a clean compounding story yet. Financial health is only 35/100, debt/equity is 1.67, and cannabis retail rarely deserves blind trust. But at 36.9% below the 52-week high, just 5.5% above the 200-day average, and with no sell-side coverage inflating expectations, the setup still leans favorable. The market is discounting too little chance that HITI's forward earnings mix has improved for real.
Remexian keeps compounding from 14.1% share, U.K. M&A closes, Canada stabilizes, and investors start underwriting durable positive earnings instead of episodic profits.
Germany sustains share and margin, Canadian expansion continues within the 20-30 store plan, and valuation moves toward a blended sales-plus-quality framework.
Canadian retail remains weak, Remexian turns volatile or lower margin than 25%, and the market keeps valuing HITI near distressed retail multiples.
No analyst coverage available to cross-check.
In the short run, the market is a voting machine, but in the long run, it is a weighing machine.
Forward earnings power is improving faster than the trailing numbers show because Q2 delivered CAD 13.9M of adjusted EBITDA and positive net income, while trailing FY2025 still shows -$0.45 EPS and a -1.3% net margin. That is why trailing P/E is useless here and the real debate is whether Germany can sustain something close to 25% gross margin and keep taking share from 14.1% higher, which would make today's 0.46x sales look too low. The moat is better than it was two years ago because scale, sourcing, loyalty, and international distribution now matter more than just adding Canadian stores, but over 3-5 years it is still only moderate because cannabis retail remains price-competitive and regulation can reshape economics quickly. AI is not a thesis driver on its own, but it should help in pricing, inventory, CRM, and procurement efficiency; regulation and the growth of legal medical cannabis in Germany matter far more than AI to the value path here.
- Remexian reached 14.1% market share in Germany, up from 6.5% since acquisition, and management says margins can stay around 25%.
- Adjusted EBITDA rose to CAD 13.9M with an 8% margin, up 160 bps y/y, while gross margin hit an eight-quarter high of 27%.
- The stock trades at just 0.46x sales versus a 3.6x peer average P/S, and the quant engine's $4.92 target implies 92.3% upside from $2.56.
- Q2 revenue was CAD 179.3M, up 30% y/y, the best quarter management says it has ever reported, showing the company is no longer dependent only on mature Canadian retail.
- Remexian gross margin jumped to 27% from 12% in Q1, with procurement costs down 30% to 40%, which matters because Germany is now the clearest source of incremental profit growth.
- Store growth is still active, with 228 stores open and 10 already added toward the 20-30 store CY2026 target, plus the 4 Northern Helm stores add CAD 8.5M annualized revenue and CAD 1.7M annualized EBITDA.
- Financing risk eased with CAD 40M BMO facilities approved, including a CAD 25M revolver and CAD 15M delayed-draw term loan, supporting working capital and expansion.
- FY2025 EPS was -$0.45, down 93.1% YoY, and net margin was -1.3%, so the business still has very little room for operational mistakes.
- Core retail demand is soft, with same-store sales down 1.2% and management calling out trade-down and fewer visits from its blue-collar customer base.
- The earnings record is erratic, including a massive miss on 2026-01-29 with EPS -0.37098 versus 0.00357 expected, which weakens confidence in any straight-line earnings recovery.
- Balance-sheet quality is only fair, with debt/equity 1.67, current ratio 1.46, and a quant Financial Health score of 35/100, while reported annual FCF is $0.0B.
| Metric | Value | Context |
|---|---|---|
| Current price | $2.56 | Reference price for valuation and scenario framing |
| Quant price target | $4.92 | 92.3% upside, Low confidence, basis: sales_quality_blend |
| FY2025 revenue | $0.4B | 6.5% YoY growth |
| FY2025 EPS | -$0.45 | -93.1% YoY, still not sustainably profitable on trailing numbers |
| FY2025 operating margin | 0.6% | Down from 1.0% in the prior fiscal year |
| FY2025 net margin | -1.3% | Shows trailing earnings remain fragile |
| Valuation | 0.46x P/S | Versus 3.6x peer average P/S |
| Balance sheet | Debt/Equity 1.67 | Current ratio 1.46, total debt $0.1B |
| Latest quarter | CAD 179.3M revenue | Record quarter, 30% y/y growth |
| Latest quarter profitability | CAD 13.9M adjusted EBITDA | 8% margin, up from 6.4% a year ago |
| Price action | -36.9% vs 52-week high | 52-week range $2.02-$4.06; price is 5.5% above 200-day average |
The biggest risk is that the Germany profit engine proves lumpier than hoped, because if Remexian margins slip below management's roughly 25% expectation while Canadian same-store sales stay at -1.2%, the current earnings recovery case breaks.
The immediate catalyst is Q3 2026 earnings on September 14, 2026, with the key watch items being Remexian margin durability near 25%, Canadian same-store sales, and progress toward the 20-30 store target.
Positioning is relatively clean. Short interest is only 744,306 shares, or 0.97% of shares with 1.4 days-to-cover, so this is not a classic squeeze setup despite the 25.8% change in short interest. Institutional ownership is light, with the top three institutions owning just 3.7%, and insiders are listed at 0.0%, which cuts both ways: there is little sponsorship today, but that also means better execution could still attract incremental buyers. The options backdrop is mildly supportive because the stated regime is positive gamma, which usually dampens forced volatility rather than amplifying it.
Core store network reached 228 stores; growth continues, but same-store sales were -1.2% due to trade-down and fewer visits.
Now the key profit-growth engine, with 14.1% market share, 27% gross margin in Q2, and management guiding go-forward margins around 25%.
Historically improved profitability after 45% y/y opex cuts in the 2024 Q3 call, but not a central driver in the current thesis.
Record quarter, with Germany/Remexian now the key profit-growth engine.
Execution has been mixed but improving. On the 2024 Q3 call, management said 2025 would mirror 2024 with 20-30 new stores plus M&A, and the current 2026 call still reiterates 20-30 stores with 10 already added and 228 stores open, so the expansion playbook has broadly held. Management also said in 2024 that Germany store entry could come by mid-2025 or sooner, but the current earnings engine is not German stores, it is Remexian distribution, so the international strategy evolved from retail-entry ambition toward medical distribution monetization. Margin credibility is better than growth-timeline credibility: in 2024 Raj Grover warned, "I don't see that happening. We're holding the line on margin. We may even go slight reduction in margin," and recent Canadian retail still faces pressure, but at the consolidated level Q2 gross margin was 27% and adjusted EBITDA margin reached 8%. The earnings beat/miss history is too volatile for high trust, with four beats and four misses in the provided run and a severe miss in January 2026, so management deserves some credit for the operating pivot but not full benefit of the doubt.
I am extremely proud to report that not only was this our best Q2 ever, but looking at the financial highlights, it was the best overall quarter we have ever reported to our shareholders.
Given these macro dynamics and our belief that we are still just getting going on leveraging our strong relationships, we feel that the Q2 results are much more representative regarding the go-forward picture for Remexian than the Q1 results.
Regarding the outlook, we reiterate our target to add 20-30 stores in Canada during this calendar year. We are already at 10.
As we previously communicated, our objective remains to complete a transaction within the next few quarters.
I don't think it materially affects us or affects us at all in terms of really bringing the margins down. I'm pretty comfortable telling you that margins can remain around 25%.
The moat comes from scale in Canadian cannabis retail, a large loyalty ecosystem, and now a differentiated cross-border medical cannabis distribution position through Remexian. The network effect is not as strong as in software, but procurement leverage, private-label potential, local market density, and supplier relationships do create cost and assortment advantages over smaller operators. Durability is moderate, not high, because illicit competition and regulation can still pressure margins, but the German share gain from 6.5% to 14.1% shows there is real operating edge where supply relationships matter.
Capital allocation has been expansion-first, with no buybacks or dividends and reported annual FCF of $0.0B in the supplied financials. The company is still using capital for store growth, bolt-on M&A like Northern Helm, and balance-sheet refinancing, which is appropriate given the low valuation but leaves little margin for missteps. Discipline looks improved because the CAD 40M BMO facilities replace near-term funding uncertainty with lower-cost flexibility, yet this is not a cash-rich self-funding story yet.
Rated BUY, Low conviction. The stock looks mispriced if the latest quarter is the new earnings base, because 0.46x sales is too cheap for a business that may have found a higher-margin international growth engine. The reason conviction stays low is simple: trailing earnings are still poor, balance-sheet quality is only fair, and execution has been uneven. The next few quarters need to show that Germany can stay near 25% margin and that Canadian retail does not deteriorate further. A downgrade would come if Remexian proves one-off or if domestic traffic weakness pushes consolidated profitability back down.
≣ Full research note tap to expand
Executive Summary
BUY, Low conviction. Rated BUY, Low conviction. The stock is down 36.9% from its 52-week high even after recent strength, yet Q2 showed a materially better earnings path with CAD 179.3M revenue, 27% gross margin, and CAD 13.9M adjusted EBITDA as Remexian in Germany became the main growth driver. The catch is that execution quality is uneven, balance-sheet flexibility is only fair, and earnings have been volatile enough to keep conviction low.
Investment Thesis
The market is still pricing HITI as if it were mainly a low-margin, structurally challenged Canadian cannabis retailer. That view is now incomplete. The latest quarter showed a different company shape: CAD 179.3M of revenue, up 30% y/y, an eight-quarter high 27% gross margin, and CAD 13.9M of adjusted EBITDA. More important than the quarter itself, the source of profit changed. Germany, through Remexian, is now the clearest marginal earnings driver, with market share up from 6.5% to 14.1% and management saying Q2 is more representative than Q1 for the go-forward picture.
That matters because HITI at $2.56 and 0.46x sales does not need perfection. It needs proof that positive earnings can become repeatable rather than episodic. If Remexian can hold around 25% gross margin, and if Canadian retail simply avoids further deterioration while the company adds stores within the 20-30 target, the earnings base should look materially better over the next year than trailing FY2025 suggests. Trailing EPS of -$0.45 is the wrong anchor for a business that just posted positive net income and free cash flow in the quarter, even if annual FCF still rounds to $0.0B in the supplied snapshot.
The case depends on three things. First, Germany must remain a real structural profit pool, not a one-quarter spike tied to shipment timing. Second, Canadian retail cannot keep sliding meaningfully from here, because same-store sales -1.2% already shows the domestic business is not carrying the thesis. Third, management must prove the ugly earnings volatility, including the January 2026 EPS miss, was noise from timing and mix rather than evidence of a fragile model.
Low conviction is appropriate because this is not a clean compounding story yet. Financial health is only 35/100, debt/equity is 1.67, and cannabis retail rarely deserves blind trust. But at 36.9% below the 52-week high, just 5.5% above the 200-day average, and with no sell-side coverage inflating expectations, the setup still leans favorable. The market is discounting too little chance that HITI's forward earnings mix has improved for real.
Key Metrics
| Metric | Value | Context |
|---|---|---|
| Current price | $2.56 | Reference price for valuation and scenario framing |
| Quant price target | $4.92 | 92.3% upside, Low confidence, basis: sales_quality_blend |
| FY2025 revenue | $0.4B | 6.5% YoY growth |
| FY2025 EPS | -$0.45 | -93.1% YoY, still not sustainably profitable on trailing numbers |
| FY2025 operating margin | 0.6% | Down from 1.0% in the prior fiscal year |
| FY2025 net margin | -1.3% | Shows trailing earnings remain fragile |
| Valuation | 0.46x P/S | Versus 3.6x peer average P/S |
| Balance sheet | Debt/Equity 1.67 | Current ratio 1.46, total debt $0.1B |
| Latest quarter | CAD 179.3M revenue | Record quarter, 30% y/y growth |
| Latest quarter profitability | CAD 13.9M adjusted EBITDA | 8% margin, up from 6.4% a year ago |
| Price action | -36.9% vs 52-week high | 52-week range $2.02-$4.06; price is 5.5% above 200-day average |
Financial Strength
The balance sheet is adequate, not strong. HITI has enough liquidity to operate and expand, shown by a 1.46 current ratio and the newly approved CAD 40M BMO facilities, but leverage is still meaningful at 1.67 debt/equity and annual free cash flow remains negligible in the provided financial snapshot. The more encouraging part is margin direction: the latest quarter's 27% gross margin and 8% adjusted EBITDA margin suggest the business mix is improving. The problem is that trailing fiscal numbers still show almost no operating cushion, so one weak quarter in Canada or one choppy quarter at Remexian can swing earnings sharply.
Competitive Position
The moat comes from scale in Canadian cannabis retail, a large loyalty ecosystem, and now a differentiated cross-border medical cannabis distribution position through Remexian. The network effect is not as strong as in software, but procurement leverage, private-label potential, local market density, and supplier relationships do create cost and assortment advantages over smaller operators. Durability is moderate, not high, because illicit competition and regulation can still pressure margins, but the German share gain from 6.5% to 14.1% shows there is real operating edge where supply relationships matter.
Management & Guidance
Management's current guide is straightforward: add 20-30 stores in calendar 2026, complete a U.K. transaction within the next few quarters, and maintain Remexian gross margin at around 25%. The near-term guide is partly de-risked because 10 stores are already added, Q3 same-store sales were said to be stable versus Q2, and financing is in place through the CAD 40M BMO package. Credibility is mixed. The company has delivered visible strategic progress, especially in Germany, but the reported earnings track record is inconsistent, including several misses and one very large miss in January 2026. Management deserves moderate credit on operations, but not a free pass on forecasts.
Segment Analysis
- Canada retail (Majority of revenue, exact FY share not disclosed in provided data): Core store network reached 228 stores; growth continues, but same-store sales were -1.2% due to trade-down and fewer visits.
- Germany / Remexian (Fast-growing minority contributor, exact FY share not disclosed in provided data): Now the key profit-growth engine, with 14.1% market share, 27% gross margin in Q2, and management guiding go-forward margins around 25%.
- E-commerce and accessories (Smaller contributor, exact current share not disclosed in provided data): Historically improved profitability after 45% y/y opex cuts in the 2024 Q3 call, but not a central driver in the current thesis.
Capital Allocation
Capital allocation has been expansion-first, with no buybacks or dividends and reported annual FCF of $0.0B in the supplied financials. The company is still using capital for store growth, bolt-on M&A like Northern Helm, and balance-sheet refinancing, which is appropriate given the low valuation but leaves little margin for missteps. Discipline looks improved because the CAD 40M BMO facilities replace near-term funding uncertainty with lower-cost flexibility, yet this is not a cash-rich self-funding story yet.
Management Execution & Track Record
Execution has been mixed but improving. On the 2024 Q3 call, management said 2025 would mirror 2024 with 20-30 new stores plus M&A, and the current 2026 call still reiterates 20-30 stores with 10 already added and 228 stores open, so the expansion playbook has broadly held. Management also said in 2024 that Germany store entry could come by mid-2025 or sooner, but the current earnings engine is not German stores, it is Remexian distribution, so the international strategy evolved from retail-entry ambition toward medical distribution monetization. Margin credibility is better than growth-timeline credibility: in 2024 Raj Grover warned, "I don't see that happening. We're holding the line on margin. We may even go slight reduction in margin," and recent Canadian retail still faces pressure, but at the consolidated level Q2 gross margin was 27% and adjusted EBITDA margin reached 8%. The earnings beat/miss history is too volatile for high trust, with four beats and four misses in the provided run and a severe miss in January 2026, so management deserves some credit for the operating pivot but not full benefit of the doubt.
Positioning & Flows
Positioning is relatively clean. Short interest is only 744,306 shares, or 0.97% of shares with 1.4 days-to-cover, so this is not a classic squeeze setup despite the 25.8% change in short interest. Institutional ownership is light, with the top three institutions owning just 3.7%, and insiders are listed at 0.0%, which cuts both ways: there is little sponsorship today, but that also means better execution could still attract incremental buyers. The options backdrop is mildly supportive because the stated regime is positive gamma, which usually dampens forced volatility rather than amplifying it.
Bull Case
- Q2 revenue was CAD 179.3M, up 30% y/y, the best quarter management says it has ever reported, showing the company is no longer dependent only on mature Canadian retail.
- Remexian gross margin jumped to 27% from 12% in Q1, with procurement costs down 30% to 40%, which matters because Germany is now the clearest source of incremental profit growth.
- Store growth is still active, with 228 stores open and 10 already added toward the 20-30 store CY2026 target, plus the 4 Northern Helm stores add CAD 8.5M annualized revenue and CAD 1.7M annualized EBITDA.
- Financing risk eased with CAD 40M BMO facilities approved, including a CAD 25M revolver and CAD 15M delayed-draw term loan, supporting working capital and expansion.
Bear Case
- FY2025 EPS was -$0.45, down 93.1% YoY, and net margin was -1.3%, so the business still has very little room for operational mistakes.
- Core retail demand is soft, with same-store sales down 1.2% and management calling out trade-down and fewer visits from its blue-collar customer base.
- The earnings record is erratic, including a massive miss on 2026-01-29 with EPS -0.37098 versus 0.00357 expected, which weakens confidence in any straight-line earnings recovery.
- Balance-sheet quality is only fair, with debt/equity 1.67, current ratio 1.46, and a quant Financial Health score of 35/100, while reported annual FCF is $0.0B.
Valuation & Price Target
Engine price target $4.92 (+92.3% vs current), Low confidence.
- P/S Multiple: $17.75 (3% weight)
- Quality-adjusted: $2.44 (20% weight)
- DCF: $7.34 (3% weight)
The rating matches the quant baseline of BUY, but with the same Low conviction for a reason. The quant target is $4.92, supported by a wide method spread between P/S Multiple $17.75, Quality-adjusted $2.44, and DCF $7.34, which already tells the story: upside exists, but quality and consistency are the debate. Agreement with the BUY call rests on the stock trading at 0.46x sales despite a record CAD 179.3M quarter, 27% gross margin, and a visibly stronger Germany mix. Conviction stays low because FY2025 still showed -$0.45 EPS, annual FCF $0.0B, and balance-sheet quality that is only middling. There is no analyst coverage to cross-check, which neither helps nor hurts the case.
Risk Assessment
Risk score 41/100 (Moderate). The biggest risk is that the Germany profit engine proves lumpier than hoped, because if Remexian margins slip below management's roughly 25% expectation while Canadian same-store sales stay at -1.2%, the current earnings recovery case breaks.
The Bottom Line
Rated BUY, Low conviction. The stock looks mispriced if the latest quarter is the new earnings base, because 0.46x sales is too cheap for a business that may have found a higher-margin international growth engine. The reason conviction stays low is simple: trailing earnings are still poor, balance-sheet quality is only fair, and execution has been uneven. The next few quarters need to show that Germany can stay near 25% margin and that Canadian retail does not deteriorate further. A downgrade would come if Remexian proves one-off or if domestic traffic weakness pushes consolidated profitability back down.
Go deeper in the app
Live charts, options analytics, the full earnings-call breakdown, price alerts, and every other stock — updated in real time.
Get Tickr